Technical Analysis for MDNA - Medicenna Therapeutics Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -6.71% | |
| Down 3 Days in a Row | Weakness | -6.71% | |
| Down 4 Days in a Row | Weakness | -6.71% | |
| Down 5 Days in a Row | Weakness | -6.71% | |
| 20 DMA Resistance | Bearish | -8.38% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 20 hours ago |
| Down 5% | about 20 hours ago |
| Down 3% | about 20 hours ago |
| Down 2% | about 20 hours ago |
| Down 1% | about 20 hours ago |
Get a Trading Assistant
- Earnings date: 2024-02-12
Medicenna Therapeutics Corp. Description
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Clinical Trial Oncology Clinical Medicine Cancers Tumor Immunotherapy Stem Cells Treatment Of Cancer Cancer Immunotherapy Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.1 |
| 52 Week Low | 0.215 |
| Average Volume | 176,510 |
| 200-Day Moving Average | 0.700 |
| 50-Day Moving Average | 1.417 |
| 20-Day Moving Average | 1.748 |
| 10-Day Moving Average | 1.764 |
| Average True Range | 0.184 |
| RSI (14) | 45.95 |
| ADX | 28.29 |
| +DI | 22.084 |
| -DI | 25.146 |
| Chandelier Exit (Long, 3 ATRs) | 1.548 |
| Chandelier Exit (Short, 3 ATRs) | 1.952 |
| Upper Bollinger Bands | 2.052 |
| Lower Bollinger Band | 1.445 |
| Percent B (%b) | 0.14 |
| BandWidth | 34.697 |
| MACD Line | 0.078 |
| MACD Signal Line | 0.132 |
| MACD Histogram | -0.0543 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.695 | ||||
| Resistance 3 (R3) | 1.703 | 1.657 | 1.668 | ||
| Resistance 2 (R2) | 1.657 | 1.615 | 1.653 | 1.658 | |
| Resistance 1 (R1) | 1.593 | 1.589 | 1.570 | 1.585 | 1.649 |
| Pivot Point | 1.547 | 1.547 | 1.535 | 1.543 | 1.547 |
| Support 1 (S1) | 1.483 | 1.505 | 1.460 | 1.475 | 1.411 |
| Support 2 (S2) | 1.437 | 1.479 | 1.433 | 1.402 | |
| Support 3 (S3) | 1.373 | 1.437 | 1.393 | ||
| Support 4 (S4) | 1.365 |
